Pioneering complete ectogenesis through an advanced ex vivo placenta platform. Safe, controlled gestation from embryo to viability—without traditional pregnancy.
For millennia, human reproduction has carried immense biological risk. At Nexaborn, we believe the future of humanity requires a safer, more equitable path to life. Our mission is to decouple gestation from maternal hazard, providing true reproductive freedom and equality. We are making pregnancy an option, not a biological mandate.
Our proprietary bioreactor mimics the exact biological conditions required for human embryo development outside the body, utilizing synthetic amniotic fluid and micro-dosed oxygenation.
A dynamically self-regulating fluid ecosystem that matches the evolving pH, temperature, and peptide requirements of an embryo in real-time, replicating the natural womb.
Our breakthrough nanotech interface connects directly to the embryonic circulatory system, offering perfectly calibrated nutrient delivery and waste removal without vascular rejection.
Automated bioreactors synthesize and administer micro-doses of essential developmental hormones, ensuring robust neurological and physiological growth metrics are met.
Experience the profound journey of parenthood without the physical toll or medical complications of pregnancy.
Eliminate the risk of preeclampsia, gestational diabetes, hemorrhage, and postpartum physical recovery. Your health remains uncompromised.
Bond with your developing child from anywhere. Our platform streams real-time biometric data, high-resolution 4D imaging, and allows you to transmit your heartbeat and voice directly into the pod.
Nexaborn removes biological barriers. We offer a path to biological parenthood for individuals with uterine infertility, same-sex couples, and those who choose an alternative to surrogacy.
Nexaborn represents a paradigm shift in the multi-billion dollar fertility and reproductive health market. Join us as we scale from R&D to global implementation.
Successful sustained development of mammalian models utilizing our proprietary umbilical interface and synthetic amniotic fluid generation.
Initiation of highly regulated, ethical FDA human clinical trials focusing on partial ectogenesis (extreme prematurity rescue) transitioning into early-stage ex vivo gestation.
Commercial launch of the Nexaborn Pod systems into specialized fertility clinics worldwide, establishing a new standard of care in reproductive medicine.
For investor inquiries, press, or early access waiting lists, connect with our team.
info@nexaborn.com